BNP Paribas Financial Markets Acquires 581,173 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• BNP Paribas Financial Markets increased its stake in BioNTech SE Sponsored ADR by 94.6% during the first quarter, now holding a total of 1,195,470 shares valued at approximately $108.86 million.
• BioNTech reported a loss of $1.60 EPS in its latest quarterly earnings, missing expectations, but noted a 102.6% increase in revenue compared to the same quarter last year, totaling $306.46 million.
• Analysts have a consensus rating of "Moderate Buy" for BioNTech's stock, with a price target averaging $135.80, indicating positive future expectations despite current market fluctuations.

BNP Paribas Financial Markets lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 94.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,195,470 shares of the company's stock after acquiring an additional 581,173 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.50% of BioNTech worth $108,859,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of BioNTech during the fourth quarter worth approximately $584,000. Tower Research Capital LLC TRC raised its position in BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares in the last quarter. Voya Investment Management LLC raised its position in BioNTech by 14.5% during the fourth quarter. Voya Investment Management LLC now owns 27,870 shares of the company's stock valued at $3,176,000 after purchasing an additional 3,520 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of BioNTech by 9.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 22,983 shares of the company's stock worth $2,619,000 after buying an additional 2,054 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in shares of BioNTech during the fourth quarter worth $298,000. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

Shares of BNTX stock traded up $1.38 during trading hours on Thursday, hitting $101.80. 159,882 shares of the company were exchanged, compared to its average volume of 921,176. The firm has a fifty day simple moving average of $109.43 and a 200 day simple moving average of $104.71. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $131.49. The stock has a market capitalization of $24.47 billion, a price-to-earnings ratio of -63.51 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same quarter in the previous year, the business earned ($3.36) EPS. The company's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Research analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BNTX. Bank of America upped their price target on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Morgan Stanley increased their price objective on shares of BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Finally, Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.